Literature DB >> 16888227

Protective effects of PACAP in excitotoxic striatal lesion.

A Tamás1, A Lubics, I Lengvári, D Reglódi.   

Abstract

The present article investigated the effects of pituitary adenylate cyclase-activating polypeptide (PACAP) treatment in a quinolinic acid (QA)-induced unilateral lesion of the striatum, a model of Huntington;s disease (HD). PACAP was given locally, preceding the lesion. Behavioral analysis was performed after 1, 10, and 30 days, when motor activity and asymmetrical signs were evaluated. Three weeks after the treatment, a catalepsy test was performed by haloperidol administration, and finally histological assessment of the striatum was done. Our results show that PACAP treatment attenuated the behavioral deficits and reduced the number of lesioned neurons in the striatum.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16888227     DOI： 10.1196/annals.1317.083

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  9 in total

1.  Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.

Authors:  N Cabezas-Llobet; L Vidal-Sancho; M Masana; A Fournier; J Alberch; D Vaudry; X Xifró
Journal:  Mol Neurobiol       Date:  2018-03-10       Impact factor: 5.590

2.  Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1.

Authors:  Paul S Baxter; Marc-Andre Martel; Aoife McMahon; Peter C Kind; Giles E Hardingham
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

3.  Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice.

Authors:  Julie Deguil; François Chavant; Claire Lafay-Chebassier; Marie-Christine Pérault-Pochat; Bernard Fauconneau; Stéphanie Pain
Journal:  Neurotox Res       Date:  2009-07-21       Impact factor: 3.911

Review 4.  Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases.

Authors:  Agnieszka Dejda; Valérie Jolivel; Steve Bourgault; Tommy Seaborn; Alain Fournier; Hubert Vaudry; David Vaudry
Journal:  J Mol Neurosci       Date:  2008-05-28       Impact factor: 3.444

5.  Passage through the Ocular Barriers and Beneficial Effects in Retinal Ischemia of Topical Application of PACAP1-38 in Rodents.

Authors:  Dora Werling; William A Banks; Therese S Salameh; Timea Kvarik; Laszlo Akos Kovacs; Alexandra Vaczy; Edina Szabo; Flora Mayer; Rita Varga; Andrea Tamas; Gabor Toth; Zsolt Biro; Tamas Atlasz; Dora Reglodi
Journal:  Int J Mol Sci       Date:  2017-03-21       Impact factor: 5.923

Review 6.  Protective effects of PACAP in ischemia.

Authors:  Dora Reglodi; Alexandra Vaczy; Eloísa Rubio-Beltran; Antoinette MaassenVanDenBrink
Journal:  J Headache Pain       Date:  2018-03-02       Impact factor: 7.277

Review 7.  Review on PACAP-Induced Transcriptomic and Proteomic Changes in Neuronal Development and Repair.

Authors:  Adam Rivnyak; Peter Kiss; Andrea Tamas; Dorottya Balogh; Dora Reglodi
Journal:  Int J Mol Sci       Date:  2018-03-29       Impact factor: 5.923

8.  Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Protects Striatal Cells and Improves Motor Function in Huntington's Disease Models: Role of PAC1 Receptor.

Authors:  Irene Solés-Tarrés; Núria Cabezas-Llobet; Benjamin Lefranc; Jérôme Leprince; Jordi Alberch; David Vaudry; Xavier Xifró
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

9.  Posttraumatic administration of pituitary adenylate cyclase activating polypeptide in central fluid percussion injury in rats.

Authors:  Erzsébet Kövesdi; Andrea Tamás; Dóra Reglodi; Orsolya Farkas; József Pál; Gábor Tóth; Péter Bukovics; Tamás Dóczi; András Büki
Journal:  Neurotox Res       Date:  2008-04       Impact factor: 3.978
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.